trending Market Intelligence /marketintelligence/en/news-insights/trending/phgShYB-w40o0VWbKZc2gg2 content esgSubNav
In This List

Adamis seeks US FDA approval for higher dose of opioid overdose therapy

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Adamis seeks US FDA approval for higher dose of opioid overdose therapy

Adamis Pharmaceuticals Corp. said the U.S. Food and Drug Administration accepted for review its application for a higher dose of naloxone to treat opioid overdose.

The company's new drug application covers an injectable version of the medicine. The agency is expected to make a decision by Oct. 31.

Naloxone works by blocking or reversing the effects of opioids, such as extreme drowsiness, slowed breathing or loss of consciousness. A nasal spray version of the drug is marketed by Adapt Pharma Operations Ltd. under the Narcan brand. Meanwhile, kaleo Inc. offers Evzio, an autoinjectable version of the opioid overdose therapy.

San Diego-based Adamis Pharmaceuticals develops and sells products for various therapeutic areas, including respiratory disease and allergy.